Table 3 Association between oral bisphosphonate use and colorectal cancer sites, Kaiser Permanente, Northern California, 1997–2011.

From: Oral bisphosphonates and colorectal cancer

 

N cases

OR

(95% CI)

Site-specific associations

Cecum

2,195

0.86

(0.72, 1.03)

Appendix

131

0.19

(0.03, 1.42)

Ascending colon

1,648

0.79

(0.63, 0.99)

Hepatic flexure of colon

541

0.84

(0.57, 1.26)

Transverse colon

830

1.15

(0.86, 1.54)

Splenic flexure of colon

348

0.63

(0.33, 1.21)

Descending colon

547

1.01

(0.64, 1.60)

Sigmoid colon

2,803

0.77

(0.61, 0.96)

Overlapping lesion of colon

61

0.55

(0.15, 2.10)

Colon, NOS

149

0.40

(0.14, 1.15)

Rectosigmoid junction

752

0.66

(0.42, 1.02)

Rectum

2,500

0.73

(0.56, 0.94)

  1. Cases and controls were matched on sex, age at time of index date (+/− 2 years), duration of membership prior to index date (+/− 1 year), race, and region of residence.
  2. The adjusted model additionally included age, smoking, alcohol use, Charlson comorbidity index, use of NSAIDs, and previous lower endoscopy.
Back to article page